Xcel Wealth Management LLC Reduces Stock Position in Pfizer Inc. $PFE

Key Points

• Xcel Wealth Management LLC reduced its holdings in Pfizer Inc. by 12.9%, selling 29,641 shares during the 2nd quarter, and now holds 199,636 shares valued at approximately $4.84 million.
• Pfizer reported a quarterly earnings per share (EPS) of $0.78, exceeding analysts' expectations of $0.58, and had a revenue of $14.65 billion, up 10.3% year-over-year.
• Analysts have varied price targets for Pfizer, with the consensus price target at $28.12, while some firms upgraded their ratings, indicating a mix of buy and hold positions among analysts.

Xcel Wealth Management LLC trimmed its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 12.9% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 199,636 shares of the biopharmaceutical company's stock after selling 29,641 shares during the quarter. Pfizer makes up about 1.4% of Xcel Wealth Management LLC's portfolio, making the stock its 21st biggest position. Xcel Wealth Management LLC's holdings in Pfizer were worth $4,839,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of PFE. Brighton Jones LLC grew its stake in Pfizer by 1,282.4% in the fourth quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company's stock valued at $17,677,000 after purchasing an additional 618,117 shares during the last quarter. Revolve Wealth Partners LLC boosted its stake in Pfizer by 12.5% in the 4th quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company's stock worth $498,000 after purchasing an additional 2,087 shares in the last quarter. Vident Advisory LLC purchased a new stake in shares of Pfizer during the fourth quarter valued at $248,000. Heck Capital Advisors LLC purchased a new position in shares of Pfizer in the fourth quarter worth about $49,000. Finally, Park Square Financial Group LLC purchased a new stake in shares of Pfizer in the 4th quarter valued at $128,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Trading Down 0.3%

NYSE PFE opened at $24.07 on Thursday. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85. The company has a market capitalization of $136.82 billion, a price-to-earnings ratio of 12.80, a price-to-earnings-growth ratio of 0.85 and a beta of 0.55. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $30.43. The company's fifty day moving average price is $24.59 and its two-hundred day moving average price is $24.18.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The business had revenue of $14.65 billion during the quarter, compared to analyst estimates of $13.43 billion. During the same period in the prior year, the company posted $0.60 EPS. The business's revenue for the quarter was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, research analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have commented on PFE. Berenberg Bank dropped their price objective on Pfizer from $28.00 to $25.00 and set a "hold" rating on the stock in a report on Thursday, May 29th. Wall Street Zen upgraded shares of Pfizer from a "hold" rating to a "buy" rating in a report on Saturday, September 20th. Bank of America boosted their target price on Pfizer from $27.00 to $28.00 and gave the stock a "neutral" rating in a research note on Wednesday, August 6th. Citigroup upped their price target on Pfizer from $25.00 to $26.00 and gave the company a "neutral" rating in a report on Wednesday, August 6th. Finally, Morgan Stanley increased their price target on shares of Pfizer from $32.00 to $33.00 and gave the stock an "equal weight" rating in a research note on Wednesday, August 6th. Two analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have given a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Hold" and a consensus price target of $28.12.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.